Custom Panel

 

Test code: GDB749

Related gene(s): AIP, ALK, ANKRD26, APC, ATM, AXIN2, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDC73, CDH1, CDK4, CDKN1B, CDKN2A, CEBPA, CHEK2, CTNNA1, DDX41, DICER1, EPCAM, ETV6, FANCC, FANCM, FH, FLCN, GALNT12, GATA2, HOXB13, IKZF1, KIT, LZTR1, MAX, MEN1, MET, MITF, MLH1, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NF2, NTHL1, PALB2, PAX5, PDGFRA, PHOX2B, PMS2, POLD1, POLE, POT1, PRKAR1A, PTCH1, PTEN, RAD51C, RAD51D, RB1, RECQL, RET, RNF43, RPS20, RTEL1, RUNX1, SAMD9, SAMD9L, SCG5/GREM1, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, SRP72, STK11, SUFU, TERC, TERT, TINF2, TMEM127, TP53, TSC1, TSC2, VHL, WT1

Test description:

We offer the option of ordering single-gene testing and/or a customized cancer panel from a list of 91 cancer susceptibility genes. The option of ordering each gene individually or in any combination allows the provider the flexibility to choose the most appropriate testing approach for their patient when an available panel is not desired.

Conditions:

  • Colorectal Cancer
  • Endometrial Cancer
  • Familial Adenomatous Polyposis (FAP)
  • Lynch Syndrome
  • Ovarian Cancer
  • Pancreatic Cancer
  • Paraganglioma
  • Pheochromocytoma
  • Renal Cancer
  • Attenuated Familial Adenomatous Polyposis (AFAP)
  • Thyroid Cancer
  • Brain Cancer
  • Breast Cancer

 
Clinical utility:

  • Identify the genetic basis of cancer for individuals who have features and/or a family history consistent with one of the hereditary cancer syndromes described above
  • Determine appropriate clinical management recommendations based on a molecular diagnosis
  • Identify family members at-risk to develop features associated with a specific hereditary cancer syndrome

 
Lab method:

  • Deletion/duplication analysis
  • Next-Gen sequencing
  • MLPA

Specimen Requirements

  • Preferred: 2-5 mL Blood – Lavender Top Tube
  • Alternative: Extracted DNA

Ordering Information

  • CPT code(s):* Varies by gene
  • Turnaround Time:** 3 weeks


*The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.
**Reporting times are typical and begin once the sample(s) are received at the GeneDx laboratory, but could be extended in situations outside GeneDx’s reasonable control.


Resources

Hereditary Cancer Requisition
Hereditary Cancer Re-requisition
GeneDx Test Information Sheet (TIS)